Anti-Amyloid Alzheimer’s Drugs in 2026: Who Qualifies, What They Do, and What Families Should Know

Why anti-amyloid Alzheimer’s drugs are still a major topic in 2026

For families facing early Alzheimer’s disease, one question keeps coming up: Do the new drugs actually help?

In 2023, the U.S. Food and Drug Administration (FDA) granted traditional approval to lecanemab (brand name Leqembi) for certain people with early Alzheimer’s disease. Since then, clinics across the country have been working through what treatment looks like in real life—who qualifies, how much benefit to expect, what the risks are, and how Medicare coverage works.

Here is the practical bottom line in 2026:

These drugs are for early symptomatic Alzheimer’s, not advanced dementia.
They can slow decline modestly, but they do not restore lost memory.
Treatment requires regular IV infusions and multiple MRIs to monitor safety.
Medicare may cover them, but registry participation and local capacity matter.

What lecanemab is—and who it is approved for

Lecanemab is a laboratory-made antibody designed to bind to amyloid-beta, a protein that builds up in the brains of people with Alzheimer’s disease. The goal is to reduce amyloid plaques, which are one of the biological hallmarks of the disease.

According to the FDA’s traditional approval announcement, lecanemab is indicated for people with:

Mild cognitive impairment (MCI) due to Alzheimer’s disease, or
Mild dementia due to Alzheimer’s disease

Importantly, patients must also have confirmed amyloid pathology—usually proven by amyloid PET scan or cerebrospinal fluid testing. The drug is not approved for moderate or advanced Alzheimer’s disease.

This matters because many people living with dementia today would not qualify under the FDA labeling.

What the CLARITY-AD trial showed—in plain language

The key evidence behind approval comes from a large randomized, placebo-controlled trial called CLARITY-AD, published in the New England Journal of Medicine. More than 1,700 participants with early Alzheimer’s were randomly assigned to receive lecanemab or placebo for about 18 months.

The main outcome was a standard rating scale called the Clinical Dementia Rating–Sum of Boxes (CDR-SB), which measures memory, thinking, and daily function.

After 18 months:

People receiving lecanemab declined more slowly than those receiving placebo.
The difference was about 0.45 points on the CDR-SB scale.

In percentage terms, that translated to roughly a 27% slowing of decline compared with placebo over 18 months.

What does that mean for families?

It does not mean memory improves.
It does not stop disease progression.
It means symptoms worsened more slowly on average.

Experts writing in JAMA have noted that while the effect is statistically significant, its clinical importance can vary by individual. Some families may view a slower decline over a year or two as meaningful. Others may feel the benefit is modest relative to the burden of treatment and monitoring.

The trial followed patients for 18 months, so longer-term effects beyond that window remain uncertain.

Safety: Understanding ARIA and why MRI monitoring is required

The main safety concern with anti-amyloid antibodies is something called amyloid-related imaging abnormalities (ARIA).

ARIA shows up on brain MRI scans and comes in two main types:

ARIA-E: brain swelling (edema)
ARIA-H: small areas of bleeding (microhemorrhages)

In the CLARITY-AD trial, ARIA occurred more often in people receiving lecanemab than placebo. Many cases were detected on MRI before causing symptoms. When symptoms occurred, they could include headache, confusion, dizziness, visual changes, or nausea.

Most cases resolved with monitoring or pausing treatment. However, serious complications, while uncommon, have been reported.

Risk is higher in people who carry the APOE ε4 gene variant, especially those with two copies. For that reason, clinicians often discuss optional genetic testing before treatment to better understand ARIA risk.

The FDA labeling requires:

A baseline MRI before starting treatment
Additional MRIs during the first several months of therapy

People with extensive microbleeds, certain unstable medical conditions, or who require some forms of anticoagulation may not be good candidates.

What treatment looks like in real life

Lecanemab is given as an intravenous infusion every two weeks.

That means:

Regular visits to an infusion center
Ongoing neurologist or memory specialist oversight
Scheduled MRIs for safety monitoring
Caregiver involvement for transportation and observation

Because the drug is only for early-stage disease, evaluation typically involves:

Formal cognitive testing
Amyloid confirmation by PET or spinal fluid
Review of MRI results

This is not a prescription that can be started in a routine primary care visit. It usually requires referral to a specialty center.

Medicare coverage and access in 2026

The Centers for Medicare & Medicaid Services (CMS) has issued national coverage guidance for monoclonal antibodies directed against amyloid.

Under current policy, Medicare covers FDA-approved anti-amyloid therapies when:

The patient meets FDA label criteria, and
Treatment is entered into a qualifying registry that collects real-world data.

This “coverage with evidence development” approach is designed to monitor safety and effectiveness in broader clinical use.

In practice, that means access depends on:

Whether a local health system participates in an approved registry
Availability of infusion capacity
Access to MRI and amyloid testing

Out-of-pocket costs vary based on Medicare plan type, supplemental insurance, and coinsurance. Families should ask about both drug costs and associated imaging and infusion fees.

What remains uncertain

Even with FDA approval and randomized trial data, important questions remain:

How durable is the benefit beyond 18 months?
Will slowing decline early translate into longer-term functional independence?
How will real-world ARIA rates compare with clinical trials?
How will health systems manage capacity as demand grows?

Removing amyloid does not guarantee symptom improvement. Alzheimer’s disease also involves tau pathology, inflammation, and vascular factors. Anti-amyloid therapy addresses one part of a complex disease.

Questions to ask a neurologist or memory specialist

Am I (or my family member) in the early stage that qualifies?
Has amyloid been confirmed?
What is the expected benefit in practical terms?
What is the ARIA risk based on MRI findings and APOE status?
How often will MRIs be required?
What are the total expected costs, including imaging?
What happens if ARIA develops?

What this means for families

Anti-amyloid drugs like lecanemab represent a new chapter in Alzheimer’s treatment—but not a cure.

For a specific group of people with early Alzheimer’s disease and confirmed amyloid, they can slow decline modestly over about 18 months. That may be meaningful for some families. For others, the risks, monitoring burden, or logistics may outweigh the benefit.

Decisions should be individualized, grounded in a clear understanding of what the evidence shows—and what it does not. A detailed discussion with a neurologist or memory specialist is essential before starting therapy.

As with many areas of medicine, progress is incremental. In 2026, the conversation is less about whether these drugs work at all—and more about who benefits enough to make treatment worthwhile.

Sources

This article is for general informational purposes only and is not medical advice. Research findings can be early, limited, or subject to change as new evidence emerges. For personal guidance, diagnosis, or treatment, consult a licensed clinician. For current outbreak or public health guidance, follow your local health department, the CDC, or another relevant public health authority.